Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

44%

4 trials in Phase 3/4

Results Transparency

133%

4 of 3 completed trials have results

Key Signals

2 recruiting4 with results

Enrollment Performance

Analytics

Phase 3

4(50.0%)

Phase 2

4(50.0%)

8Total

Phase 3(4)

Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT03624010Phase 2Completed

Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients

Role: lead

NCT07436689Phase 3Enrolling By Invitation

Long-Term Open-Label Extension Study of Oral Levosimendan

Role: lead

NCT07288398Phase 3Recruiting

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

Role: lead

NCT00174980Phase 2Terminated

Study of Oxycyte in Severe Closed Head Injury

Role: lead

NCT05983250Phase 3Recruiting

LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF

Role: lead

NCT03541603Phase 2Completed

Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF

Role: lead

NCT02025621Phase 3Completed

Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass

Role: lead

NCT02973620Unknown

Levosimendan Compassionate Use in Pediatric Patients With Advanced Decompensated Heart Failure

Role: lead

NCT00908063Phase 2Terminated

Safety and Tolerability of Oxycyte in Patients With Traumatic Brain Injury (TBI)

Role: lead

All 9 trials loaded